PPIDT00294
Drug Information
| Name | Ravulizumab |
|---|---|
| Sequence | XVQLVQSGAEVKKPGASVKVSCKASGHIFSNYWIQWVRQAPGQGLEWMGEILPGSGHTEYTENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVLHEALHSHYTQKSLSLSLG |
| DrugBank_ID | DB11580 |
| Type | biotech |
| Indication | Ravulizumab is indicated for the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH).[L39690] It is also indicated for the treatment of adult and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). However, the FDA advises against the use of ravulizumab for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).[L39690] Ravulizumab is also indicated for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.[L39690,L39700] It is indicated for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive.[L50396] The European Commission approved ravulizumab for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) in adults and children with a body weight of 10 kg or more with the following conditions: hemolysis with clinical symptoms indicative of high disease activity or clinically stable after having been treated with eculizumab for at least the past six months. Ravulizumab is also indicated for the treatment of hemolytic uremic syndrome (aHUS) in patients with a body weight of 10 kg or more who are either complement inhibitor treatment-naïve or have received [eculizumab] for at least 3 months and have evidence of response to eculizumab.[L39700] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Subcutaneous |
245 mg
|
| Injection, solution, concentrate | Intravenous |
10 mg / mL
|
| Injection, solution, concentrate | Intravenous |
1100 mg/11mL
|
| Injection, solution, concentrate | Intravenous |
1100 MG
|
| Injection, solution, concentrate | Intravenous |
300 mg/3mL
|
| Injection, solution, concentrate | Intravenous |
300 mg/30mL
|
| Injection, solution, concentrate | Intravenous |
300 MG
|
| Kit; solution | Subcutaneous |
245 mg/3.5mL
|
| Solution | Intravenous |
1100 mg / 11 mL
|
| Solution | Intravenous |
300 mg / 3 mL
|
| Solution, concentrate | Intravenous |
10000000 mg
|
| Injection, solution, concentrate | Intravenous |
100 mg/mL
|